Licensing · GCC · Announced 14 Oct 2026
Inventia Healthcare → ADCAN Pharma
Licensing deal between Inventia Healthcare (India) and ADCAN Pharma (United Arab Emirates), announced 14 Oct 2026.
Parties: Inventia Healthcare Limited (India) → ADCAN Pharma (United Arab Emirates)
- Deal type
- Licensing
- Value
- Not stated
- Territory
- UAE (production); stated scope UAE, KSA and rest of Middle East
- Therapeutic area
- Cardiovascular
- Asset
- Cardiology and Diabetes product portfolio — licensing plus technology transfer toward local production at ADCAN (specific molecules undisclosed)
- Announced
- 14 Oct 2026
Our analysis
Why this matters
This is one of five licensing and technology-transfer agreements ADCAN Pharma signed at CPHI Milan 2026 — but the Inventia deal is the one where the data tells the sharpest story. Our Levant registration dataset shows Inventia already holds ~100 product registrations across seven MENA markets (41 of them filed in 2026 alone): dapagliflozin, metformin ER, telmisartan combinations, rivaroxaban — sold through SPI and Al Razi in Saudi and Azalea in UAE. This deal localizes products with proven regional demand rather than betting on new molecules. For CEOs: ADCAN is assembling a chronic-disease manufacturing platform at conference speed. For BD: licensing-plus-tech-transfer on top of an existing import footprint is the lowest-risk localization structure available.
The full analysis is free to read with a work email on this page.